Agomab Therapeutics NV 6-K filed 2026-09-11

Agomab Therapeutics NV, which trades on Nasdaq under the ticker AGMB, filed this Form 6-K on 2026-09-11. A 6-K is the report a foreign private issuer uses to furnish information to the SEC, and the cover page shows the company files annual reports on Form 20-F. The company lists its principal executive offices in Antwerpen, Belgium. It describes itself as a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases. The SEC classifies it under Biological Products, (No Diagnostic Substances) and as a non-accelerated filer and emerging growth company. The filing's only substance is a press release, furnished as Exhibit 99.1, which the company says is not deemed "filed" for purposes of Section 18 of the Exchange Act. The press release reports that shareholders approved all resolutions at the company's Special and Extraordinary General Shareholders' Meeting held on September 11, 2026. The approved resolutions included the appointment of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors. The release quotes Chief Executive Officer Tim Knotnerus welcoming both. Patel says he expects to bring experience in translational medicine and clinical development. The directors' biographies are not in the filing; the release says they are available on the company's website. Vote tallies, committee assignments, director compensation, and whether any existing directors departed are also not in the filing. The second approved item may matter more to readers tracking the capital structure. Shareholders approved a consolidation and split adjustment of outstanding pre-IPO warrants, which aligns those warrants with the share split implemented in connection with Agomab's IPO in February 2026. The number of warrants affected, the adjustment ratio, and exercise prices are not in the filing excerpt.